MarketingRx: Biogen's new CEO talks DTC for depression drug candidate; AbbVie debuts Skyrizi TV ad for Crohn’s
New Biogen CEO Chris Viehbacher is already looking ahead to marketing and advertising strategies for zuranolone, Biogen’s major depressive disorder and postpartum candidate with partner Sage Therapuetics now awaiting an FDA decision, according to analysts at SVB Securities.
In a note last week, SVB analysts detailed a meeting with a “forthcoming” Viehbacher in early January in which he talked about zuranolone’s potential launch, among other topics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.